- Home
- VCNX vs UPXI Comparison
VCNX vs UPXI Comparison
Compare VCNX & UPXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCNX
- UPXI
- Stock Information
- Founded
- VCNX 2001
- UPXI 2018
- Country
- VCNX United States
- UPXI United States
- Employees
- VCNX N/A
- UPXI N/A
- Industry
- VCNX Biotechnology: Pharmaceutical Preparations
- UPXI Medicinal Chemicals and Botanical Products
- Sector
- VCNX Health Care
- UPXI Health Care
- Exchange
- VCNX Nasdaq
- UPXI Nasdaq
- Market Cap
- VCNX 4.5M
- UPXI 5.3M
- IPO Year
- VCNX N/A
- UPXI 2021
- Fundamental
- Price
- VCNX $3.22
- UPXI $4.10
- Analyst Decision
- VCNX
- UPXI Hold
- Analyst Count
- VCNX 0
- UPXI 1
- Target Price
- VCNX N/A
- UPXI $25.00
- AVG Volume (30 Days)
- VCNX 167.3K
- UPXI 2.5M
- Earning Date
- VCNX 11-29-2024
- UPXI 11-29-2024
- Dividend Yield
- VCNX N/A
- UPXI N/A
- EPS Growth
- VCNX N/A
- UPXI N/A
- EPS
- VCNX N/A
- UPXI N/A
- Revenue
- VCNX $388,000.00
- UPXI $83,980,115.00
- Revenue This Year
- VCNX N/A
- UPXI $18.98
- Revenue Next Year
- VCNX N/A
- UPXI $8.09
- P/E Ratio
- VCNX N/A
- UPXI N/A
- Revenue Growth
- VCNX N/A
- UPXI 27.11
- 52 Week Low
- VCNX $1.39
- UPXI $2.17
- 52 Week High
- VCNX $13.02
- UPXI $33.00
- Technical
- Relative Strength Index (RSI)
- VCNX 48.87
- UPXI 42.27
- Support Level
- VCNX $2.87
- UPXI $4.52
- Resistance Level
- VCNX $3.43
- UPXI $5.94
- Average True Range (ATR)
- VCNX 0.53
- UPXI 1.42
- MACD
- VCNX 0.05
- UPXI -0.34
- Stochastic Oscillator
- VCNX 23.22
- UPXI 0.58
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
About UPXI Upexi Inc.
Upexi Inc is an innovator in aggregation, accelerating Amazon and eCommerce businesses by combining consumer data and vertical integration to scale brands in multiple industries, while lowering costs with a growing distribution network.